Apolipoprotein C-III in the high-density lipoprotein proteome of cerebral lacunar infarction patients impairs its anti-inflammatory function

Lv,Pu; Zhao,Mingming; Liu,Yuanyuan; Jin,Haiqiang; Cui,Wei; Fan,Chenghe; Teng,Yuming; Zheng,Lemin; Huang,Yining

doi:10.3892/ijmm.2017.3216

Apolipoprotein C-III in the high-density lipoprotein proteome of cerebral lacunar infarction patients impairs its anti-inflammatory function

Authors:
- Pu Lv
- Mingming Zhao
- Yuanyuan Liu
- Haiqiang Jin
- Wei Cui
- Chenghe Fan
- Yuming Teng
- Lemin Zheng
- Yining Huang
View Affiliations

Affiliations: Department of Health Care, China-Japan Friendship Hospital, Ministry of Health, Beijing 100029, P.R. China, The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, and Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides of Ministry of Health, Peking University Health Science Center, Beijing 100191, P.R. China, Department of Neurology, Peking University First Hospital, Beijing 100034, P.R. China
Published online on: October 27, 2017 https://doi.org/10.3892/ijmm.2017.3216
Pages: 61-68
Copyright: © Lv et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High-density lipoprotein (HDL) proteomic study has identified substantial changes associated with various disease states. In the current study, the HDL proteomes in patients with cerebral lacunar infarction (LACI) and control subjects were investigated. A total of 12 LACI patients without evident large vessel occlusions and 12 controls were enrolled in the study. The HDL fraction from each sample was isolated from the plasma by ultracentrifugation. The protemics of the HDL were investigated using nano liquid chromatography coupled to tandem mass spectrometry. There were 55 proteins identified as differentially expressed in the LACI and control groups. Among the 55 proteins, 33 were upregulated and 22 were downregulated in the patients with LACI. The identified proteins were associated with numerous molecular functions, including lipid and cholesterol transport, lipid metabolism, inflammatory response, the complement and coagulation pathway, metal ion metabolism, hemostasis and endopeptidase inhibitory activity. Serum amyloid A, apolipoprotein C (apoC-III) and apolipoprotein A-II (apoA-II) were selected to confirm the proteomics results via western blotting. HDL from the LACI patients exhibited an impaired ability to inhibit the binding of THP-1 cells to endothelial cells compared with the controls (P<0.01). ApoC-III-rich HDL also had a significantly reduced ability to inhibit the binding of THP-1 cells to endothelial cells (P<0.01). The expression of vascular cell adhesion molecule-1 protein by the endothelial cells exhibited a similar pattern of response to the different HDL samples. In conclusion, the present study demonstrates major modifications of the HDL proteome in patients with LACI. The ApoC-III enrichment of the HDL of patients with LACI may cause a reduction in the anti-inflammatory ability of HDL, which may contribute to the progression of the disease.

View Figures

View References

1	Havel RJ, Eder HA and Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1345–1353. 1955. View Article : Google Scholar : PubMed/NCBI
2	Kontush A and Chapman MJ: Antiatherogenic small, dense HDL–guardian angel of the arterial wall. Nat Clin Pract Cardiovasc Med. 3:144–153. 2006. View Article : Google Scholar : PubMed/NCBI
3	Davidson WS and Thompson TB: The structure of apolipoprotein A-I in high density lipoproteins. J Biol Chem. 282:22249–22253. 2007. View Article : Google Scholar : PubMed/NCBI
4	Kontush A and Chapman MJ: Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 58:342–374. 2006. View Article : Google Scholar : PubMed/NCBI
5	Karlsson H, Leanderson P, Tagesson C and Lindahl M: Lipoproteomics II: Mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 5:1431–1445. 2005. View Article : Google Scholar : PubMed/NCBI
6	Heller M, Stalder D, Schlappritzi E, Hayn G, Matter U and Haeberli A: Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics. 5:2619–2630. 2005. View Article : Google Scholar : PubMed/NCBI
7	Rezaee F, Casetta B, Levels JH, Speijer D and Meijers JC: Proteomic analysis of high-density lipoprotein. Proteomics. 6:721–730. 2006. View Article : Google Scholar : PubMed/NCBI
8	Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, et al: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 117:746–756. 2007. View Article : Google Scholar : PubMed/NCBI
9	Tan Y, Liu TR, Hu SW, Tian D, Li C, Zhong JK, Sun HG, Luo TT, Lai WY and Guo ZG: Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions. PLoS One. 9:e942642014. View Article : Google Scholar : PubMed/NCBI
10	Yan LR, Wang DX, Liu H, Zhang XX, Zhao H, Hua L, Xu P and Li YS: A pro-atherogenic HDL profile in coronary heart disease patients: An iTRAQ labelling-based proteomic approach. PLoS One. 9:e983682014. View Article : Google Scholar : PubMed/NCBI
11	Lepedda AJ, Nieddu G, Zinellu E, De Muro P, Piredda F, Guarino A, Spirito R, Carta F, Turrini F and Formato M: Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: Identification of serum amyloid A as a potential marker. Oxid Med Cell Longev. 385214:2013. View Article : Google Scholar
12	Ståhlman M, Fagerberg B, Adiels M, Ekroos K, Chapman JM, Kontush A and Borén J: Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: Impact on small HDL particles. Biochim Biophys Acta. 1831:1609–1617. 2013. View Article : Google Scholar : PubMed/NCBI
13	Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, Heinemann A and Marsche G: Uremia alters HDL composition and function. J Am Soc Nephrol. 22:1631–1641. 2011. View Article : Google Scholar : PubMed/NCBI
14	Mangé A, Goux A, Badiou S, Patrier L, Canaud B, Maudelonde T, Cristol JP and Solassol J: HDL proteome in hemodialysis patients: A quantitative nanoflow liquid chromatography-tandem mass spectrometry approach. PLoS One. 7:e341072012. View Article : Google Scholar : PubMed/NCBI
15	Kopecky C, Genser B, Drechsler C, Krane V, Kaltenecker CC, Hengstschläger M, März W, Wanner C, Säemann MD and Weichhart T: Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis. Clin J Am Soc Nephrol. 10:224–231. 2015. View Article : Google Scholar :
16	Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, Lee TD and Reddy ST: Proteomic profiling following immunoaffinity capture of high-density lipoprotein: Association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 64:1828–1837. 2012. View Article : Google Scholar : PubMed/NCBI
17	Chait A, Han CY, Oram JF and Heinecke JW: Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: Markers or mediators of cardiovascular disease. J Lipid Res. 46:389–403. 2005. View Article : Google Scholar : PubMed/NCBI
18	Chei CL, Yamagishi K, Kitamura A, Kiyama M, Imano H, Ohira T, Cui R, Tanigawa T, Sankai T, Ishikawa Y, et al: CIRCS Investigators: High-density lipoprotein subclasses and risk of stroke and its subtypes in Japanese population: The Circulatory Risk in Communities Study. Stroke. 44:327–333. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR and Barter PJ: Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol. 18:1450–1455. 1998. View Article : Google Scholar : PubMed/NCBI
20	Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M and Fogelman AM: Antiinflammatory properties of HDL. Circ Res. 95:764–772. 2004. View Article : Google Scholar : PubMed/NCBI
21	Fisher CM: The arterial lesions underlying lacunes. Acta Neuropathol. 12:1–15. 1968. View Article : Google Scholar : PubMed/NCBI
22	Ogata J, Yamanishi H and Ishibashi-Ueda H: Review: Role of cerebral vessels in ischaemic injury of the brain. Neuropathol Appl Neurobiol. 37:40–55. 2011. View Article : Google Scholar
23	Sorci-Thomas MG and Thomas MJ: Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol. 62:239–246. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hsieh JY, Chang CT, Huang MT, Chang CM, Chen CY, Shen MY, Liao HY, Wang GJ, Chen CH, Chen CJ, et al: Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults. Anal Chem. 85:11440–11448. 2013. View Article : Google Scholar : PubMed/NCBI
25	Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ and Kontush A: Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: Relevance to antioxidative function. Arterioscler Thromb Vasc Biol. 29:870–876. 2009. View Article : Google Scholar : PubMed/NCBI
26	Patel B and Markus HS: Magnetic resonance imaging in cerebral small vessel disease and its use as a surrogate disease marker. Int J Stroke. 6:47–59. 2011. View Article : Google Scholar : PubMed/NCBI
27	Turin TC, Kita Y, Rumana N, Nakamura Y, Takashima N, Ichikawa M, Sugihara H, Morita Y, Hirose K, Okayama A, et al: Ischemic stroke subtypes in a Japanese population: Takashima Stroke Registry, 1988–2004. Stroke. 41:1871–1876. 2010. View Article : Google Scholar : PubMed/NCBI
28	Liu D, Ji L, Tong X, Pan B, Han JY, Huang Y, Chen YE, Pennathur S, Zhang Y and Zheng L: Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter A1. Am J Physiol Cell Physiol. 301:C739–C748. 2011. View Article : Google Scholar : PubMed/NCBI
29	Eng JK, McCormack AL and Yates JR: An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom. 5:976–989. 1994. View Article : Google Scholar : PubMed/NCBI
30	Kimura T, Tomura H, Mogi C, Kuwabara A, Damirin A, Ishizuka T, Sekiguchi A, Ishiwara M, Im DS, Sato K, et al: Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem. 281:37457–37467. 2006. View Article : Google Scholar : PubMed/NCBI
31	Huang W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009. View Article : Google Scholar :
32	Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, et al: STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41:D808–D815. 2013. View Article : Google Scholar :
33	Gordon SM, Deng J, Lu LJ and Davidson WS: Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res. 9:5239–5249. 2010. View Article : Google Scholar : PubMed/NCBI
34	Bernelot Moens SJ, van Capelleveen JC and Stroes ESG: Inhibition of ApoCIII: The next CSK9? Curr Opin Lipidol. 25:418–422. 2014. View Article : Google Scholar : PubMed/NCBI
35	Kawakami A and Yoshida M: Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb. 16:6–11. 2009. View Article : Google Scholar : PubMed/NCBI
36	Feig JE, Shamir R and Fisher EA: Atheroprotective effects of HDL: Beyond reverse cholesterol transport. Curr Drug Targets. 9:196–203. 2008. View Article : Google Scholar : PubMed/NCBI
37	Ansell BJ, Fonarow GC and Fogelman AM: The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 18:427–434. 2007. View Article : Google Scholar : PubMed/NCBI
38	Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM and Navab M: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 96:2882–2891. 1995. View Article : Google Scholar : PubMed/NCBI
39	Blokhina O, Virolainen E and Fagerstedt KV: Antioxidants, oxidative damage and oxygen deprivation stress: A review. Ann Bot (Lond). 91:179–194. 2003. View Article : Google Scholar
40	Katoh N and Nakagawa H: Detection of haptoglobin in the high-density lipoprotein and the very high-density lipoprotein fractions from sera of calves with experimental pneumonia and cows with naturally occurring fatty liver. J Vet Med Sci. 61:119–124. 1999. View Article : Google Scholar : PubMed/NCBI
41	Nielsen MJ, Petersen SV, Jacobsen C, Oxvig C, Rees D, Møller HJ and Moestrup SK: Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein. Blood. 108:2846–2849. 2006. View Article : Google Scholar : PubMed/NCBI